利空突袭！深夜，暴跌超21%！

Group 1: Company Performance - Novo Nordisk's stock price opened significantly lower, dropping over 21% as of the report time, while Eli Lilly's stock fell nearly 6% [6][8]. - Novo Nordisk revised its full-year sales and profit guidance downwards, citing weak growth expectations for its flagship weight loss drug Wegovy in the critical U.S. market [9]. Group 2: Financial Forecasts - The company now expects sales growth (at constant exchange rates) to be between 8% and 14%, down from a previous target of 13% to 21%. Operating profit growth is now projected at 10% to 16%, compared to earlier expectations of 21% and 24% [9]. - The downward revision is attributed to competition faced by Wegovy and its sister diabetes drug Ozempic, as well as the presence of cheaper generic versions of Wegovy in the U.S. market [9]. Group 3: Management Changes - Novo Nordisk announced that Maziar Mike Doustdar will replace Lars Fruergaard Jorgensen as the new CEO, following Jorgensen's unexpected removal in May [9].